CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Cladribine +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03012672
NCT03012672Phase 2Completed

Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study

University of Washington·interventional·Posted Jan 6, 2017·Updated Mar 8, 2022

In Brief

A Phase 2 clinical trial evaluating Cladribine, Cytarabine, and 4 other interventions for Acute Leukemia of Ambiguous Lineage and 2 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This randomized pilot trial studies how well higher or lower dose cladribine, cytarabine, and mitoxantrone work in treating medically less fit patients with newly diagnosed acute myeloid leukemia or myeloid neoplasm. Drugs used in chemotherapy, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cladribine, cytarabine, and mitoxantrone at higher or lower dose may work better in treating patients with newly diagnosed acute myeloid leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 6, 2017
Enrollment StartDec 30, 2016
Primary CompletionDec 10, 2020
Study CompletionFeb 26, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.5 years ago

Interventions

Cladribinedrug

Given IV

Cytarabinedrug

Given IV

Granulocyte Colony-Stimulating Factorbiological

Given SC

Mitoxantrone Hydrochloridedrug

Given IV

Quality-of-Life Assessmentother

Ancillary studies

Questionnaire Administrationother

Ancillary studies